Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on March 19, 2026 regarding:1. Approved investment upto USD 100 million in the equity share capital of Cipla (EU) Limited, a whollyowned subsidiary of the Company for the purpose of providing onward financial assistance to InvaGen Pharmaceuticals Inc., wholly-owned subsidiary of Cipla (EU) Limited, to meet its capital expenditure, working capital requirements and other general corporate purposes.2. Approved Scheme of Amalgamation of Inzpera Healthsciences Limited ( Transferor Company ), wholly owned subsidiary with the Company ( Transferee Company ). The Scheme of Amalgamation is subject to necessary approvals required under the Companies Act, 2013, including approval of the Hon bleNational Company Law Tribunal, Mumbai. The proposed amalgamation will not have any material impact on the financials of the Company.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cipla's board, meeting on March 19, 2026, approved a USD 100 million investment in its wholly-owned UK subsidiary Cipla (EU) Limited, which will onward fund InvaGen Pharmaceuticals Inc. (a US subsidiary) for capex, working capital, and general corporate purposes. The board also approved a Scheme of Amalgamation to merge Inzpera Healthsciences Limited (its wholly-owned subsidiary focused on paediatric pharmaceuticals) into Cipla, pending NCLT Mumbai approval. The amalgamation involves no cash consideration, no share exchange ratio (Inzpera shares will be cancelled), and no change to Cipla's shareholding pattern, with no material impact on financials. Additionally, Mr P R Ramesh was designated Vice-Chairman effective April 1, 2026, and Independent Director Mr Robert Stewart will not seek re-appointment after his term ends May 13, 2026.
The USD 100M infusion is internal capital movement to a wholly-owned arm, not requiring new external funds or affecting shareholder dilution. The amalgamation is a group restructuring with no financial or shareholding impact, so near-term stock reaction is likely neutral.